Foreign Drug Makers To Cut Staffs Through India Sales Reps
This article was originally published in PharmAsia News
Executive Summary
About 10 foreign drug makers are cutting back on their sales forces in India by as many as 200 representatives as part of global reduction of expenses. In India, most of the companies face union laws and are attempting to reduce staff by various techniques, such as changing job titles. The cuts are believed taking place in India because the country has price controls that reduce the productivity level of sales representatives. The move by multinationals is the opposite of Indian pharmas, which are hiring as many sales people as they can attract. (Click here for more
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.